Tools

LEADER 03804nam 2200553 i 4500

001 ssj0002500674;

003 WaSeSS;

005 20251212090320.0;

006 m d ;

007 cr n ;

008 190620s2020 si a sb 001 0 eng d;

020 a| 9789814800808q| hardcover;

020 a| 9814800805q| hardcover;

020 z| 9780429353116q| eBook;

035 a| (WaSeSS)ssj0002500674;

042 a| pcc;

044 9| Singapore;

049 a| EREEa| NEHH;

050 4 a| TP248.E5b| P43 2020;

060 00 a| QU 135;

082 04 a| 660.6342| 23;

245 00 a| Pharmaceutical biocatalysis.p| Chemoenzymatic synthesis of active pharmaceutical ingredientsh| [electronic resource] /c| edited by Peter Grunwald.;

246 1 a| Chemoenzymatic synthesis of active pharmaceutical ingredients;

260 a| Singapore :b| Jenny Stanford Publishing,c| [2020];

300 a| xxiv, 838 pages :b| illustrations ;c| 24 cm.;

490 1 a| Jenny Stanford series on biocatalysis ;v| volume 5;

504 a| Includes bibliographical references and index.;

506 a| Available only to authorized users.;

520 a| This volume provides an insight into the future strategies for commercial biocatalysis with a focus on sustainable technologies, together with chemoenzymatic and biotechnological approaches to synthesize various types of approved and new active pharmaceutical ingredients (APIs) via proven and latest synthetic routes using single-step biocatalytic or enzyme cascade reactions. Many of these drugs act as enzyme inhibitors, as discussed in a chapter with a variety of examples. The targeted enzymes are involved in diseases such as different cancers, metastatic and infectious diseases, osteoporosis, and cardiovascular disorders. The biocatalysts employed for API synthesis include hydrolytic enzymes, alcohol dehydrogenases, laccases, imine reductases, reductive aminases, peroxygenases, cytochrome P450 enzymes, polyketide synthases, transaminases, and halogenases. Many of them have been improved with respect to their properties by engineering methods. The book discusses the syntheses of drugs, including alkaloids and antibiotics, non-ribosomal peptides, antimalarial and antidiabetic drugs, prenylated xanthones, antioxidants, and many important (chiral) intermediates required for the synthesis of pharmaceuticals.;

538 a| Mode of access: World Wide Web;

650 12 a| Enzymesx| chemical synthesis0| https://id.nlm.nih.gov/mesh/D004798Q000138=| ^A917771;

650 12 a| Enzymesx| pharmacology0| https://id.nlm.nih.gov/mesh/D004798Q000494=| ^A1326911;

650 22 a| Enzyme Therapy0| https://id.nlm.nih.gov/mesh/D057487?| UNAUTHORIZED;

650 22 a| Biocatalysis0| https://id.nlm.nih.gov/mesh/D055162?| UNAUTHORIZED;

650 22 a| Drug Development0| https://id.nlm.nih.gov/mesh/D000076722=| ^A1389347;

655 0 a| Electronic books.=| ^A491897;

700 1 a| Grunwald, Peter,d| 1941-?| UNAUTHORIZED;

830 0 a| Jenny Stanford series on biocatalysis ;v| v. 5.?| UNAUTHORIZED;

856 40 z| Full text available from Taylor & Francis eBooksu| https://go.openathens.net/redirector/ecu.edu?url=https%3A%2F%2Fwww.taylorfrancis.com%2Fbooks%2F9780429353116;

947 a| (OCoLC)1104914264;

949 a| CLICK ON WEB ADDRESSw| ASISh| JOYNER188;

949 a| CLICK ON WEB ADDRESSw| ASISh| HSL77;

949 a| CLICK ON WEB ADDRESSw| ASISh| JMUSIC60;

596 a| 1 3 4;

998 a| 6679846;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6679846-1001l| JNETm| JOYNERr| Ys| Yt| JNESSBKu| 12/19/2025x| EBOOKz| JERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6679846-2001l| HSLELECm| HSLr| Ys| Yt| HEBKu| 12/19/2025x| EBOOKz| HERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6679846-3001l| MNETm| JMUSICr| Ys| Yt| MNESSBKu| 12/19/2025x| EBOOKz| JERESOURCE;

Pharmaceutical biocatalysis. / edited by Peter Grunwald.

Other author	Grunwald, Peter, 1941-
Format	Electronic
Publication Info	Singapore : Jenny Stanford Publishing, [2020]
Description	xxiv, 838 pages : illustrations ; 24 cm.
Supplemental Content	Full text available from Taylor & Francis eBooks
Subjects	Enzymes--chemical synthesis. Enzymes--pharmacology. Enzyme Therapy Biocatalysis Drug Development

Variant title	Chemoenzymatic synthesis of active pharmaceutical ingredients
Series	Jenny Stanford series on biocatalysis ; volume 5 Jenny Stanford series on biocatalysis ; v. 5. UNAUTHORIZED
Abstract	This volume provides an insight into the future strategies for commercial biocatalysis with a focus on sustainable technologies, together with chemoenzymatic and biotechnological approaches to synthesize various types of approved and new active pharmaceutical ingredients (APIs) via proven and latest synthetic routes using single-step biocatalytic or enzyme cascade reactions. Many of these drugs act as enzyme inhibitors, as discussed in a chapter with a variety of examples. The targeted enzymes are involved in diseases such as different cancers, metastatic and infectious diseases, osteoporosis, and cardiovascular disorders. The biocatalysts employed for API synthesis include hydrolytic enzymes, alcohol dehydrogenases, laccases, imine reductases, reductive aminases, peroxygenases, cytochrome P450 enzymes, polyketide synthases, transaminases, and halogenases. Many of them have been improved with respect to their properties by engineering methods. The book discusses the syntheses of drugs, including alkaloids and antibiotics, non-ribosomal peptides, antimalarial and antidiabetic drugs, prenylated xanthones, antioxidants, and many important (chiral) intermediates required for the synthesis of pharmaceuticals.
Bibliography note	Includes bibliographical references and index.
Access restriction	Available only to authorized users.
Technical details	Mode of access: World Wide Web
Genre/form	Electronic books.
ISBN	9789814800808 hardcover
ISBN	9814800805 hardcover
ISBN	eBook

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

Pharmaceutical biocatalysis. / edited by Peter Grunwald.

Click here for more information about this title

Availability